PF-04449913

DRUG7 trials

Conditions

Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia (CMML)GlioblastomaHematologic MalignanciesMyelodysplastic Syndrome (MDS)Recurrent Adult Acute Myeloid LeukemiaSolid Tumors

Phase 1

A Study Of PF-04449913 In Select Hematologic Malignancies

CompletedNCT00953758

PfizerHematologic Malignancies

Start: 2010-03-03End: 2013-02-27Updated: 2024-04-25

A Study Of PF-04449913 Administered Alone In Select Solid Tumors

CompletedNCT01286467

PfizerSolid Tumors

Start: 2011-05-11End: 2012-12-28Updated: 2024-03-06

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

CompletedNCT02038777

PfizerAcute Myeloid Leukemia

Start: 2014-03-25End: 2023-12-28Updated: 2025-02-26

Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma

CompletedNCT03466450

Grupo Español de Investigación en NeurooncologíaGlioblastoma

Start: 2018-03-15End: 2023-11-29Updated: 2024-03-28

Phase 2

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

CompletedNCT01546038

PfizerAcute Myeloid Leukemia

Start: 2012-06-27End: 2019-03-04Updated: 2020-03-03

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

CompletedNCT01841333

University of Colorado, DenverAdult Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia

Start: 2013-04-29End: 2020-02-04Updated: 2022-01-25

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

CompletedNCT01842646

H. Lee Moffitt Cancer Center and Research InstituteChronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS)

Start: 2013-08-29End: 2021-06-10Updated: 2021-06-14

2025-12-04

Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high‐risk myelodysplastic syndromes

Cancer Science2024-02-073 citations

Safety and efficacy of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial.

Journal of Clinical Oncology2022-06-011 citations

Exposure–response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer

Expert Review of Clinical Pharmacology2021-05-172 citations

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Annals of Hematology2021-03-1952 citations

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.

2020-09-036 citations

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.

2020-07-1427 citations

Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.

Journal of Clinical Oncology2020-05-2010 citations

Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML: BRIGHT AML 1003 post hoc analysis.

Journal of Clinical Oncology2020-05-201 citations

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Blood2019-11-1312 citations

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Blood2019-11-132 citations

Abstract LB-009: Biomarkers correlating with overall survival (OS) and response to glasdegib and intensive or nonintensive chemotherapy in patients with acute myeloid leukemia (AML)

Cancer Research2019-07-011 citations

Abstract LB-009: Biomarkers correlating with overall survival (OS) and response to glasdegib and intensive or nonintensive chemotherapy in patients with acute myeloid leukemia (AML)

Clinical Research (Excluding Clinical Trials)2019-07-01

PF272 GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE

HemaSphere2019-06-012 citations

PF292 LOW‐DOSE CYTARABINE WITH OR WITHOUT GLASDEGIB IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: LONG‐TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL

HemaSphere2019-06-011 citations

PS1030 COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY IS A STRONG PREDICTOR OF NON-RELAPSE MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION

HemaSphere2019-06-01

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.

Journal of Clinical Oncology2019-05-206 citations

New FDA Approved Therapies for AML & Impact on the Older Population

Oncology Times2019-03-14

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Leukemia2018-12-16473 citations

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Blood2018-11-295 citations

5 more papers not shown

PF-04449913

Sponsors

Conditions

Phase 1

Phase 2

Related Papers